
|Videos|October 21, 2022
Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer
Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer.
Advertisement
Episodes in this series

Now Playing
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Hereditary Ovarian Cancer Genes Found Beyond Traditionally High-Risk Groups
2
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
3
Medicaid Expansion Associated With Lower Mortality in NSCLC
4
ACIP Delayed Hepatitis B Vaccine Schedule Vote Amid Safety Controversy
5













































